BNF 73 (March 2017) is the authoritative guide to prescribing, dispensing and administering medicines for all healthcare professionals. Access to the latest edition of BNF is vital for healthcare professionals.
Compiled with the advice of clinical experts and continually updated to reflect the latest evidence from credible sources worldwide, this essential reference provides up-to-date guidance on prescribing, dispensing, and administering medicines.
Not only does the BNF include a widely accepted framework for the drug management of common diseases, it also includes details of medicines prescribed in the UK, with special reference to their uses, cautions, contraindications, side-effects and dosage. This allows treatment to be tailored to the individual needs of each patient.
The BNF is updated in print every six months by an expert team of pharmacists; validated by a network of leading clinicians from many spheres of clinical practice; and published under the authority of a Joint Formulary Committee. The BNF reflects current best practice as well as legal and professional guidelines relating to the use of medicines. As a result it is used widely as a touchstone reference, and cited by regulatory bodies and courts as a source of authority.
Compiled with the advice of clinical experts and continually updated to reflect the latest evidence from credible sources worldwide, this essential reference provides up-to-date guidance on prescribing, dispensing, and administering medicines.
Not only does the BNF include a widely accepted framework for the drug management of common diseases, it also includes details of medicines prescribed in the UK, with special reference to their uses, cautions, contraindications, side-effects and dosage. This allows treatment to be tailored to the individual needs of each patient.
The BNF is updated in print every six months by an expert team of pharmacists; validated by a network of leading clinicians from many spheres of clinical practice; and published under the authority of a Joint Formulary Committee. The BNF reflects current best practice as well as legal and professional guidelines relating to the use of medicines. As a result it is used widely as a touchstone reference, and cited by regulatory bodies and courts as a source of authority.
New content and updates:
Updated guidance for conditions including anal fissure, coeliac disease, dementia, exocrine pancreatic insufficiency, food allergy, multiple sclerosis and short bowel syndrome. New prescribing guidance for biological and biosimilar medicines.
New drug monographs alirocumab, blinatumomab, brivaracetam, ceftobiprole, clevidipine, elvitegravir, isavuconazole, nivolumab and panobinostat.
New safety information about fire risk with paraffin-based skin emollients on dressings and clothing and advice on minimising the risk of infections when being treated with idelalisib.
Updated guidance on starting routine for oral progestogen-only contraceptives and the use of sodium glucose co-transporter 2 inhibitors as monotherapy for treating type 2 diabetes.
Updated guidance for conditions including anal fissure, coeliac disease, dementia, exocrine pancreatic insufficiency, food allergy, multiple sclerosis and short bowel syndrome. New prescribing guidance for biological and biosimilar medicines.
New drug monographs alirocumab, blinatumomab, brivaracetam, ceftobiprole, clevidipine, elvitegravir, isavuconazole, nivolumab and panobinostat.
New safety information about fire risk with paraffin-based skin emollients on dressings and clothing and advice on minimising the risk of infections when being treated with idelalisib.
Updated guidance on starting routine for oral progestogen-only contraceptives and the use of sodium glucose co-transporter 2 inhibitors as monotherapy for treating type 2 diabetes.
Download link:
No comments:
Post a Comment